Identified a possible biomarker for the appearance of stones in cystinuria
A new study identified a possible biomarker for the appearance of cystine stones in the urinary tract in a murine model of cystinuria.
A new study identified a possible biomarker for the appearance of cystine stones in the urinary tract in a murine model of cystinuria.
The hematology team, from IDIBELL and ICO, has published an article in the journal Blood Advances that proposes this index as a tool to identify patients with higher risk to be transferred to the Intensive Care Unit (ICU) after hematopoietic stem cell transplant.
The results of a clinical trial, published in the New England Journal of Medicine, show that Tebentafusp is the first drug to increase overall survival in metastatic uveal melanoma, highly aggressive cancer that causes death in 50% of cases in less than a year.
According to the study, the higher mortality should be attributed to the advanced aged and the worst preoperative health.
IDIBELL’s strategic plan is closely linked to the human resources strategy for researchers. Here we present some of the concrete actions that we are carrying out in recruitment and selection, working conditions, ethical and professional aspects, and training and development.
Not all countries have the same organizational models, but the payment system between the government and hospitals seems to be a determining factor for the health policy evaluation.
Older adults who are overweight or obese who stick most closely to the Mediterranean diet preserve their cognitive performance and even improve their abilities after three years
The Generalitat of Catalonia has awarded IDIBELL a co-financed project of 2 million euros that will consolidate Personalized Medicine on the Bellvitge campus. The money will be used to create and improve infrastructures that allow the management and storage of patient samples and derived data, ensuring their integrity and traceability.
A study led by IDIBELL and the ICO has analyzed genetic data from thousands of patients with inflammatory bowel disease through an innovative statistical approach that has made it possible to identify new susceptibility genes to this disease.
A team from IDIBELL and the University of Barcelona has devised two treatments based on this innovative technology: a derivative of morphine that does not generate addition, a new treatment against psoriasis. Also they used this technology to determine the adenosine role in pain transmission.